يعرض 1 - 3 نتائج من 3 نتيجة بحث عن '"Alanko, T.V."', وقت الاستعلام: 0.41s تنقيح النتائج
  1. 1
    Academic Journal
    611P Pembrolizumab (pembro) monotherapy for docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Updated analyses with 4 years of follow-up from cohorts 1-3 of the KEYNOTE-199 study

    المؤلفون: Antonarakis, E.S., Piulats, J.M., Gross-Goupil, M., Goh, J.C., Vaishampayan, U.N., De Wit, R., Alanko, T.V., Fukasawa, S., Tabata, K., Feyerabend, S., Berger, R., Ojamaa, K., Hoimes, C.J., Sezer, A., Omlin, A.G., Yachnin, J., Niu, C., Poehlein, C.H., Schloss, C., de Bono, J.S.

    المساهمون: GlaxoSmithKline, Meso Scale Diagnostics, Merck, Janssen Pharmaceuticals, Roche, Merck Sharp and Dohme, Sanofi, Bayer Fund, AstraZeneca, AbbVie, Pfizer, Astellas Pharma US, Boehringer Ingelheim, Bristol-Myers Squibb, Teva Pharmaceutical Industries

    المصدر: Annals of Oncology ; volume 32, page S651-S652 ; ISSN 0923-7534

    الاتاحة: http://dx.doi.org/10.1016/j.annonc.2021.08.1124
    https://api.elsevier.com/content/article/PII:S0923753421033536?httpAccept=text/xml
    https://api.elsevier.com/content/article/PII:S0923753421033536?httpAccept=text/plain

    View record in BASE

    أضف إلى المفضلة
  2. 2
    Academic Journal
    231P Phase II study of pembrolizumab in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer (mCRPC): Updated follow-up of cohorts (C) 1-3 from KEYNOTE-199

    المؤلفون: Goh, J.C.H., Piulats, J.M., Gross-Goupil, M., Vaishampayan, U.N., de Wit, R., Alanko, T.V., Fukasawa, S., Tabata, K., Feyerabend, S., Berger, R., Wu, H., Kim, J., Schloss, C., de Bono, J.S., Antonarakis, E.S.

    المساهمون: Merck Sharp and Dohme

    المصدر: Annals of Oncology ; volume 31, page S1331-S1332 ; ISSN 0923-7534

    الاتاحة: http://dx.doi.org/10.1016/j.annonc.2020.10.451
    https://api.elsevier.com/content/article/PII:S0923753420429424?httpAccept=text/xml
    https://api.elsevier.com/content/article/PII:S0923753420429424?httpAccept=text/plain

    View record in BASE

    أضف إلى المفضلة
  3. 3
    Academic Journal
    1025P Fully intravenous delivery regimen of oncolytic adenovirus coding for TNFa and IL-2 (TILT-123) in patients with advanced solid cancers.

    المؤلفون: Pakola, S.A.1 (AUTHOR), Jalkanen, K.2 (AUTHOR), Alanko, T.V.3 (AUTHOR), Clubb, J.H.A.4 (AUTHOR), Quixabeira, D.C.A.4 (AUTHOR), Jirovec, E.1 (AUTHOR), Kudling, T.1 (AUTHOR), Arias, V.1 (AUTHOR), Korpisaari, R.3 (AUTHOR), Jaakkola, M.2 (AUTHOR), Kononen, J.T.3 (AUTHOR), Sormunen, J.3 (AUTHOR), Pellinen, T.5 (AUTHOR), Haybout, L.4 (AUTHOR), Kistler, C.4 (AUTHOR), Sorsa, S.4 (AUTHOR), Havunen, R.4 (AUTHOR), Santos, J.M.4 (AUTHOR), Cervera-Carrascon, V.4 (AUTHOR), Hemminki, A.1 (AUTHOR)

    المصدر: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS692-S693. 2p.

    مصطلحات موضوعية: *CANCER patients, *ADENOVIRUSES


    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS – أرسل هذا البحث بالبريد الإلكتروني – حفظ البحث – جدول التنبيهات: لا شيء